CTOs on the Move

Aptinyx

www.aptinyx.com

 
Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aptinyx.com
  • 1801 Maple Avenue Suite 4300
    Evanston, IL USA 60201
  • Phone: 847.871.0377

Executives

Name Title Contact Details

Funding

Aptinyx raised $65M on 05/10/2016
Aptinyx raised $35M on 01/14/2020

Similar Companies

Provista Life Sciences

Provista Life Sciences is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hinsdale Hematology-Oncology Associates

Hinsdale Hematology-Oncology Associates is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genesis Bioventures

Genesis Bioventures, Inc. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CureVac

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA.

Novascreen Biosciences Corporation

Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.